Description
Keytruda (pembrolizumab) Concentrate for Infusion 25 mg/ml. – 4 ml. Vial
Keytruda (pembrolizumab) is a medication used for the treatment of various types of cancer. It is a type of immunotherapy known as a checkpoint inhibitor, which works by helping the immune system to identify and attack cancer cells. Keytruda is administered as a concentrate for intravenous infusion, with a concentration of 25 mg/ml. in a 4 ml. vial.
Indications
Keytruda is indicated for the treatment of the following types of cancer:
- Advanced melanoma
- Non-small cell lung cancer
- Head and neck squamous cell carcinoma
- Classical Hodgkin lymphoma
- Urothelial carcinoma
- Gastric cancer
- Cervical cancer
Mechanism of Action
Keytruda works by blocking the PD-1/PD-L1 pathway, which is a mechanism used by cancer cells to evade detection by the immune system. By inhibiting this pathway, Keytruda helps to activate the immune system to recognize and attack cancer cells.
Dosage and Administration
The recommended dose of Keytruda is determined by the type of cancer being treated and the patient’s weight. It is administered as an intravenous infusion over a specified period of time. The infusion should be administered by a healthcare professional experienced in the use of cancer therapies.
Side Effects
Common side effects of Keytruda may include:
- Fatigue
- Nausea
- Diarrhea
- Rash
- Joint pain
More serious side effects may include immune-related adverse events such as pneumonitis, colitis, hepatitis, thyroid disorders, and adrenal insufficiency. It is important to discuss any side effects with your healthcare provider.
Precautions
Before starting treatment with Keytruda, inform your healthcare provider about any medical conditions you have, including if you are pregnant or breastfeeding. Keytruda may cause harm to an unborn baby, so effective contraception should be used during treatment and for a period of time afterward.
Storage and Handling
Keytruda should be stored in a refrigerator at a temperature of 2-8°C (36-46°F). Do not freeze the medication. Protect the vial from light by keeping it in its original carton until ready for use. Once diluted for infusion, Keytruda should be used within a specified timeframe.
Conclusion
Keytruda (pembrolizumab) is a valuable treatment option for various types of cancer, offering patients the potential for improved outcomes and quality of life. It is important to follow your healthcare provider’s instructions for dosing and monitoring while receiving Keytruda therapy. If you have any questions or concerns about Keytruda, do not hesitate to discuss them with your healthcare team.
